 Connection
Kyle Molina to Treatment Outcome
This is a "connection" page, showing publications Kyle Molina has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.344 |
|
|
|
-
Krsak M, Klimpl D, Mueller SW, Morrisette T, Grimshaw AA, Chastain D, Steuber T, Sah R, Henao-Martinez AF, Molina KC. Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies. Pharmacotherapy. 2025 11; 45(11):754-763.
Score: 0.080
-
Krsak M, Morrisette T, Damioli L, Flues B, Liu EW, Zhou AY, Msdi AS, McLeod C, Akundi S, Redell M, Molina KC. Can Oritavancin Be Used for Treatment and/or Suppressive Antimicrobial Therapy of Bone and Joint Infections Caused by Vancomycin-resistant Enterococcus faecium ? Clin Orthop Relat Res. 2025 03 14; 483(7):1225-1233.
Score: 0.077
-
Molina KC, Webb BJ, Kennerley V, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Aggarwal NR, Ginde AA. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5. BMC Infect Dis. 2024 Aug 08; 24(1):802.
Score: 0.074
-
Al Musawa M, El Ghali A, Morrisette T, Banks AL, Saeedi M, Mahoney M, Salam M, Sinclair E, Chen B, Molina KC, Thomas M, Zeuli J, Webb AJ, Holger DJ, Tupayachi-Ortiz MG, Bouchard J, Veve MP, Eubank TA, Raja K, Campion M, Stevens RW, Rybak MJ. Beyond traditional tetracyclines: a real-world evaluation of effectiveness and safety of omadacycline therapy for complex bacterial infections. BMC Infect Dis. 2026 May 25; 26(1).
Score: 0.021
-
Kunz Coyne AJ, Judd C, Lucas K, Al Musawa M, Van Helden S, Holger D, Althubyani A, Yost C, VanDorf S, Mynatt R, Kufel WD, Hayes J, Deri CR, Wrenn RH, Slaton CN, Morrisette T, Davis M, Cabanilla MG, Shald E, White BP, Sassine J, Truong J, Rosenberg J, Andrade J, Cerenzio J, Medvedeva N, Ha D, Eubank TA, Garey KW, Biagi M, Todd M, Kang-Birken SL, Rux C, Molina KC, Jankowski CA, Claeys KC, Venugopalan V, Veve MP, Orzol C, Eshaya M, Caniff KE, Bleick C, Rybak MJ. Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. Antimicrob Agents Chemother. 2026 06 03; 70(6):e0026826.
Score: 0.021
-
Helden SRV, Coyne AJK, Alosaimy S, Molina KC, Kang-Birken SL, Andrade J, King MA, Claeys KC, Hobbs ALV, Perkins Iii NB, Agee J, DeKerlegand A, Biagi M, Veve MP, Tart S, Gore T, Jones BM, Pullinger BM, Schrack MR, Cosimi R, Herbin SR, Judd C, Musawa MA, Rybak MJ. Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis. BMC Infect Dis. 2025 Dec 29; 25(1):1754.
Score: 0.020
-
Kunz Coyne AJ, Alosaimy S, Lucas K, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs ALV, Agee J, Perkins NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Zhao JJ, Witucki P, Rybak MJ. Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes. Microbiol Spectr. 2025 Oct 07; 13(10):e0056525.
Score: 0.020
-
Jenrette JE, Coronato K, Miller MA, Molina KC, Quinones A, Jacknin G. Prospective evaluation of single-dose aminoglycosides for treatment of complicated cystitis in the emergency department. Acad Emerg Med. 2024 07; 31(7):649-655.
Score: 0.018
-
Johnson TM, Molina KC, Miller MA, Kiser TH, Huang M, Mueller SW. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. Int J Antimicrob Agents. 2021 Apr; 57(4):106310.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|